This reflects the pleiotropic effects of IL-2 and the importance of identifying the optimal dose of low-dose IL-2 therapy in human trials of CHIKV arthritis to boost Tregs and Treg/Teff ratios without enhancing Teff cells. Here, IL2 is linked to arthritic joint disease.